Close Menu

David Challen has been appointed to the board of directors of Amersham PLC, Amersham Biosciences’ UK-based parent company. Challen is currently vice-chairman of Citigroup’s European Investment Bank. Prior to this, Challan was co-chairman at Schroder Salomon Smith Barney, after Schroder’s investment banking business — where he was chairman — merged with Salomon Smith Barney.

 

Story Landis has been appointed director of the National Institute of Neurological Disorders and Stroke.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.